{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451560333
| IUPAC_name = N-propyl-N-(4-pyridinyl)-1H-indol-1-amine
| image = Besipirdine structure.png
| width = 220

<!--Clinical data-->
| tradename =
| pregnancy_category =
| legal_status = Unscheduled
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 119257-34-0
| ATC_prefix = none
| PubChem = 60691
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 95PY16J933
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2106094
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 54696
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C16H17N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h3-11,13H,2,12H2,1H3
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = OTPPJICEBWOCKD-UHFFFAOYSA-N

<!--Chemical data-->
| C=16 | H=17 | N=3
| molecular_weight = 251.326 g/mol
| smiles = CCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
}}

'''Besipirdine''' (besipirdine hydrochloride, or HP749), an indole-substituted analog of 4-aminopyridine, is a [[nootropic]] drug developed for the treatment of [[Alzheimer's disease]] (AD).<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name = Hsu>{{cite journal
 | pmid = 1818073
| year = 1991
| author1 = Hsu
| first1 = R. S.
| title = Determination of HP 749, a potential therapeutic agent for Alzheimer's disease, in plasma by high-performance liquid chromatography
| journal = Journal of Chromatography
| volume = 572
| issue = 1–2
| pages = 352–9
| last2 = Dileo
| first2 = E. M.
| last3 = Chesson
| first3 = S. M.
| last4 = Klein
| first4 = J. T.
| last5 = Effland
| first5 = R. C.
 | doi=10.1016/0378-4347(91)80503-5
}}</ref>

== History ==
Besipirdine was first considered for the treatment of obsessive-compulsive disorder ([[OCD]]).  [[Hoechst AG|Hoechst-Roussel Pharmaceuticals, Inc.]] (Hoecst AG) filed a patent in July 1993 protecting the use of N-(pyridinyl)-1H-indol-1-amines, including besipirdine, for the treatment of OCD, supported by preliminary data gathered from rat studies {{cite patent |country=US |number=5356910 A |status=patent}}.  In 1995, Hoechst AG filed a patent protecting the production of besipirdine, this time describing its memory-enhancing, analgetic and antidepressant qualities {{cite patent |country=US |number=5459274 A|status=patent}} .  With increasing research on besipirdine uncovering its effects on the cholinergic system, Hoechst AG filed a patent in the following year to protect substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents
{{cite patent
 |country=WO
 |number=1997004777 A1
 |status= application
 |title=Use off unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents
 |pubdate=1997-02-13
 |fdate=1996-07-08
 |pridate=1995-07-27
 |invent1= Huger FP, Kongasamut S, Smith CP, Tang L
 |assign1= Hoechst Marion Roussel Inc
}}.  In the midst of Phase II clinical studies of besipirdine in Alzheimer's disease, Hoechst AG merged with [[Rhône-Poulenc]] S.A. to form [[Aventis]] Pharma Limited.  Under the new company Aventis, besipirdine ultimately failed in Phase III clinical trials due to severe cardiovascular side effects observed in a few patients in separate studies.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Sramek">{{cite journal | doi = 10.1016/0024-3205(95)02068-T| pmid = 7674813| title = A "bridging" (safety/tolerance) study of Besipirdine Hydrochloride in patients with Alzheimer's disease| journal = Life Sciences| volume = 57| issue = 12| pages = 1241–8| year = 1995| last1 = Sramek | first1 = J. J. | last2 = Viereck | first2 = C. | last3 = Jacob Huff | first3 = F.| last4 = Wardle | first4 = T. | last5 = Hourani | first5 = J. | last6 = Stewart | first6 = J. A. | last7 = Cutler | first7 = N. R. }}</ref>  In January 2004, [http://urogene.free.fr/ UroGene] acquired exclusive development and commercialization rights to besipirdine from Aventis in order to study its application in urology
{{cite patent
 |country=WO
 |number=2005035496 A1
 |status= application
 |title=Process for the preparation of n-amino substituted heterocyclic compounds
 |pubdate=2005-04-21
 |fdate=2004-10-01
 |pridate=2003-10-03
 |invent1= Dubberke S, Hanna RD, Lee GE, Mueller-Lehar J, Utz R, Weiberth F
 |assign1= Aventis Pharma Inc
}}.  In February 2007, UroGene filed its own patent protecting the crystal form of besipirdine chlorhydrate, its production process, and its applications in the pharmaceutical field.  The drug is currently undergoing Phase III development for treatment of Lower Urinary Tract Dysfunctions
{{cite patent
 |country=WO
 |number=2007096777 A2
 |status= application
 |title=Crystal form of besipirdine chlorhydrate, process preparation and use thereof
 |pubdate=2007-08-30
 |fdate=2007-02-20
 |pridate=2007-02-30
 |invent1= Bienayme H, Ferte J
 |assign1= Urogene
}}.

== Mechanism of Action ==
As a member of the [[aminopyridine]] class, besipirdine enhances the release of [[acetylcholine]] by blocking [[M-channel]]s, voltage-gated K<sup>+</sup> channels, increasing neuronal excitation by depolarizing the cell.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Sramek" /><ref name="Hubbard">{{cite journal
 | pmid = 7560249
| year = 1995
| author1 = Hubbard
| first1 = J. W.
| title = The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey
| journal = Journal of clinical pharmacology
| volume = 35
| issue = 7
| pages = 688–96
| last2 = Hsu
| first2 = R. S.
| last3 = Griffiths
| first3 = L
| last4 = Natarajan
| first4 = C
| last5 = Dean
| first5 = R
| last6 = Dileo
| first6 = E. M.
| last7 = Hintze
| first7 = T. H.
 | doi=10.1002/j.1552-4604.1995.tb04109.x
}}</ref><ref name=Klein>{{cite journal | pmid = 8558529| year = 1996| author1 = Klein| first1 = J. T.| title = Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease| journal = Journal of Medicinal Chemistry| volume = 39| issue = 2| pages = 570–81| last2 = Davis| first2 = L| last3 = Olsen| first3 = G. E.| last4 = Wong| first4 = G. S.| last5 = Huger| first5 = F. P.| last6 = Smith| first6 = C. P.| last7 = Petko| first7 = W. W.| last8 = Cornfeldt| first8 = M| last9 = Wilker| first9 = J. C.| last10 = Blitzer| first10 = R. D.| last11 = Landau| first11 = E| last12 = Haroutunian| first12 = V| last13 = Martin| first13 = L. L.| last14 = Effland| first14 = R. C.| doi = 10.1021/jm9506433}}</ref>  Additionally, besipirdine antagonizes the noradrenergic [[α2 receptor]], increasing electrically-stimulated and spontaneous [<sup>3</sup>H]norepinephrine release from cortical tissue slices, and inhibits norepinephrine uptake.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Sramek" /><ref name="Hubbard"/><ref name=Klein /><ref name="Kongasamut">{{cite journal | doi = 10.1016/0014-2999(96)00002-7| pmid = 8741167| title = Frequency-dependent inhibition of neurotransmitter release by besipirdine and HP 184| journal = European Journal of Pharmacology| volume = 300| issue = 1–2| pages = 71–4| year = 1996| last1 = Tang | first1 = L. | last2 = Kongsamut | first2 = S. }}</ref><ref name = Francis>{{cite journal
 | pmid = 10071091
| year = 1999
| author1 = Francis
| first1 = P. T.
| title = The cholinergic hypothesis of Alzheimer's disease: A review of progress
| journal = Journal of neurology, neurosurgery, and psychiatry
| volume = 66
| issue = 2
| pages = 137–47
| last2 = Palmer
| first2 = A. M.
| last3 = Snape
| first3 = M
| last4 = Wilcock
| first4 = G. K.
| pmc = 1736202
 | doi=10.1136/jnnp.66.2.137
}}</ref>  The exact pathway is not yet understood but it has been shown that besipirdine does not open sodium channels, so its consequential effect on norephinephrine release may be Ca<sup>2+</sup>-independent.<ref name = Kongsamut>{{cite journal
 | pmid = 1909035
| year = 1991
| author1 = Wagner
| first1 = K. D.
| title = Lithium and hair loss in childhood
| journal = Psychosomatics
| volume = 32
| issue = 3
| pages = 355–6
| last2 = Teicher
| first2 = M. H.
| doi = 10.1016/S0033-3182(91)72077-X
}}</ref>  Further, [<sup>3</sup>H]norepinephrine release seems to be dependent on frequency and concentration of besipirdine in that higher frequency of stimulation causes a concentration-dependent inhibition of voltage-dependent K<sup>+</sup> channels, which leads to inhibition of norepinephrine release.<ref name="Kongasamut" /><ref name="Kongasamut" /><ref name="CraigP">{{cite journal | doi = 10.1007/BF01006816| pmid = 7891842| title = HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes| journal = Neurochemical Research| volume = 19| issue = 10| pages = 1265–70| year = 1994| last1 = Smith | first1 = C. P. | last2 = Huger | first2 = F. P. | last3 = Petko | first3 = W. | last4 = Kongsamut | first4 = S. }}</ref>

== Medical Uses ==

=== Alzheimer's Disease ===
The most successful treatments for AD have been strategies targeting the [[Alzheimer's disease#Cholinergic hypothesis|cholinergic activity]] in the central nervous system, like [[acetylcholinesterase inhibitors]].<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>  Other treatments target the [[Alzheimer's disease#Other hypotheses|adrenergic system]] and have been shown to improve memory deficits associated with AD.  It was hypothesized that simultaneous treatment for both cholinergic and adrenergic deficits would be more effective than treatment that targeted individual systems alone.  Besipirdine was shown to target dysfunctional cholinergic and adrenergic systems in Alzheimer's disease.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Sramek" /><ref name="Hubbard"/><ref name = Klein /> It has been suggested as an anticonvulsant because of its adrenergic effects.  Its effects on the cholinergic system may improve memory and cognitive deficits symptomatic of AD.<ref name="Kongasamut" /><ref name = Smith>{{cite journal
 | pmid = 8581286
| year = 1995
| author1 = Tang
| first1 = L
| title = Effects of besipirdine at the voltage-dependent sodium channel
| journal = British Journal of Pharmacology
| volume = 116
| issue = 5
| pages = 2468–72
| last2 = Smith
| first2 = C. P.
| last3 = Huger
| first3 = F. P.
| last4 = Kongsamut
| first4 = S
| pmc = 1909035
 | doi=10.1111/j.1476-5381.1995.tb15097.x
}}</ref>

=== Other ===
Besipirdine was originally suggested as a treatment for OCD due to its effects on the adrenergic and serotonergic systems.<ref name = Woods>{{cite journal
 | pmid = 8879677
| year = 1996
| author1 = Woods-Kettelberger
| first1 = A. T.
| title = Besipirdine (HP 749) reduces schedule-induced polydipsia in rats
| journal = Brain Research Bulletin
| volume = 41
| issue = 2
| pages = 125–30
| last2 = Smith
| first2 = C. P.
| last3 = Corbett
| first3 = R
| last4 = Szewczak
| first4 = M. R.
| last5 = Roehr
| first5 = J. E.
| last6 = Bores
| first6 = G. M.
| last7 = Klein
| first7 = J. T.
| last8 = Kongsamut
| first8 = S
 | doi=10.1016/s0361-9230(96)00163-3
}}</ref>  "In vitro" studies of besipirdine indicated its potency in [[Serotonin reuptake inhibitor|inhibiting serotonin reuptake]] in addition to [[Norepinephrine reuptake inhibitor|norepinephrine reuptake]].<ref name="CraigP" /><ref name="Woods"/>  "In vivo", besipirdine showed efficacy in reducing schedule-induced polydipsia (SIP) in rats.<ref name = Platt>{{cite book
 | pmid = 18428677
| year = 2008
| author1 = Platt
| first1 = B
| title = Current Protocols in Neuroscience
| editor=Jacqueline N. Crawley
| volume = Chapter 9
| pages = Unit 9.27
| last2 = Beyer
| first2 = C. E.
| last3 = Schechter
| first3 = L. E.
| last4 = Rosenzweig-Lipson
| first4 = S
| doi = 10.1002/0471142301.ns0927s43
| chapter = Schedule-Induced Polydipsia: A Rat Model of Obsessive-Compulsive Disorder
| isbn = 0-471-14230-1
}}</ref>  The drug's anticonvulsant properties ultimately led Hoechst AG to pursue it as a treatment for Alzheimer's disease.
After its discontinuation in the mid-90's, besipirdine was re-evaluated as an oral treatment for [[Overactive bladder|Over Active Bladder]] (OAB) and is currently undergoing Phase III clinical trials, under UroGene.<ref name = Perez>{{cite journal
 | pmid = 21071917
| year = 2011
| author1 = Pérez-Martínez
| first1 = F. C.
| title = Halothane-anesthetized rabbit: A new experimental model to test the effects of besipirdine and duloxetine on lower urinary tract function
| journal = Urologia Internationalis
| volume = 86
| issue = 2
| pages = 210–9
| last2 = Vela-Navarrete
| first2 = R
| last3 = Virseda
| first3 = J
| last4 = Ocaña
| first4 = A. V.
| last5 = Lluel
| first5 = P
| last6 = Rekik
| first6 = M
| last7 = Bienaymé
| first7 = H
| last8 = Ferté
| first8 = J
| last9 = Attali
| first9 = P
| last10 = Palea
| first10 = S
| doi = 10.1159/000321226
}}</ref><ref name= Sacco>{{cite journal |vauthors=Sacco E, Bientinesi R |title= Future Perspective in Pharmacological Treatment Options for Overactive Bladder Syndrome |journal= European Urological Review |volume=7 |issue= 2 |pages=120–6 |date=April 2012}}</ref>  Interest in besipirdine as a treatment for OAB was piqued by its known effects on the adrenergic system.  In isolated studies, besipirdine showed greater potency than [[duloxetine]] on bladder capacity, [[Micturition|micturition volume]], intercontraction interval, and an increase in striated sphincter EMG activity.<ref name="Perez"/><ref name= Haab>{{cite journal |vauthors=Haab F, Vela-Navarrete R, Perez-Martinez F, Castilla-Reparaz C, Ferte J, Bienayme H, Attali P |title= Effects of besipirdine on acetic acid-induced bladder irritation in rabbits. Comparison with duloxetine |journal=http://www.ics.org/Abstracts/Publish/44/000064.pdf}}</ref>

== Pharmacology ==
Besipirdine primarily acts to enhance both cholinergic and adrenergic neurotransmission in the central nervous system.  It is administered orally<ref name="Hsu"/><ref name="Sramek" /><ref name="Hubbard"/> at a maximum tolerated dose (MTD) of 50&nbsp;mg BID.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Hsu"/><ref name="Sramek" /><ref name=Cutler>{{cite journal | doi = 10.1016/0006-3223(95)94593-L| title = Tolerability and pharmacodynamics of besipirdine in Alzheimer's disease| journal = Biological Psychiatry| volume = 37| issue = 9| pages = 643| year = 1995| last1 = Cutler | first1 = N. R. | last2 = Sramek | first2 = J. J. | last3 = Viereck | first3 = C.| last4 = Stewart | first4 = J.| last5 = Huff | first5 = F. J. }}</ref>  In Phase II clinical trials, patients were administered 5&nbsp;mg or 20&nbsp;mg BID doses of besipirdine.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Hsu"/><ref name="Sramek" />  Its N-despropyl metabolite, P86-7480, exhibits transient vasoconstrictor effects, producing a pressor effect of 16 ± 4&nbsp;mm Hg after intravenous administration of 0.1&nbsp;mg/kg, in monkey, rat and dog models.<ref name="Sramek" /><ref name="Hubbard"/><ref name = Nordstrom>{{cite journal
 | pmid = 9103515
| year = 1997
| author1 = Hubbard
| first1 = J. W.
| title = Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog
| journal = The Journal of Pharmacology and Experimental Therapeutics
| volume = 281
| issue = 1
| pages = 337–46
| last2 = Nordstrom
| first2 = S. T.
| last3 = Smith
| first3 = C. P.
| last4 = Brooks
| first4 = K. M.
| last5 = Laws-Ricker
| first5 = L
| last6 = Zhou
| first6 = L
| last7 = Vargas
| first7 = H. M.
}}</ref>

== Pharmacokinetics ==
The pharmacokinetics of besipirdine have been studied in conscious monkey.  The calculated elimination half-life (t<sub>1/2</sub>) of besipirdine and P86-7480 after oral administration of 10, 20, and 40&nbsp;mg/kg doses is 7.4 ± 2.1 hours.  The t<sub>1/2</sub> after intravenous administration of 10&nbsp;mg/kg is 1.5 hours.  Besipirdine is cleared through the kidneys at 0.13 ± 0.04 mL/min/kg; only 1% of the administered dose is excreted unused via the kidneys.<ref name="Hubbard"/>  In humans, using doses up to 30&nbsp;mg, the t<sub>1/2</sub> of besipirdine and P86-7480 were calculated as 3 hours, and 5.5–7 hours, respectively.  Peak plasma concentrations of besipirdine and P86-7480 were calculated as 1.5–2 hours, and 2–3 hours, respectively.<ref name="Sramek" />

== Adverse Effects ==
Besipirdine is reported to be well-tolerated.  More severe adverse effects, such as bradycardia and postural hypotension, may have been a result of a high ratio of adrenergic to cholinergic potency caused by the metabolite P86-7480, which has direct vasoconstrictor effects.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Sramek" />  Some studies suggest that the effects of besipirdine on cognition are reversible after withdrawal from treatment, indicating that the efficacy of the drug is primarily symptomatic and not neuroprotective.<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>

=== General ===
{{Plainlist|
* Nausea and vomiting<ref name="Sramek" />
* Dry mouth<ref name="Sramek" />
* Headache<ref name="Sramek" />
* Rash<ref name="Sramek" />
* Eye disorder<ref name="Sramek" />
* Urinary frequency<ref name="Sramek" />
* Mouth ulceration<ref name="Sramek" />
* Loss of appetite<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>
* Dizziness<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>
* Paresthesia<ref name="Sramek" />
* General pain<ref name="Sramek" />

=== Cardiovascular ===
* Bradycardia<ref name="Sramek" />
* Postural hypotension<ref name="Sramek" />
* Premature ventricular contractions<ref name="Sramek" />
* Angina<ref name="Sramek" />
* Arrhythmia<ref name="Sramek" />

=== Gastrointestinal ===
* Gastrointestinal disorder<ref name="Sramek" />
* Flatulence<ref name="Sramek" />
* Constipation<ref name="Sramek" />

=== Sleep ===
* Insomnia<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>
* Somnolence<ref name="Sramek" />

=== Psychological ===
* Mood changes<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref><ref name="Sramek" />
* Agitation<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>
* Nervousness<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>
* Abnormal thinking<ref name = Huff>{{cite journal
 | pmid = 8727171
| year = 1996
| author1 = Huff
| first1 = F. J.
| title = A treatment and withdrawal trial of besipirdine in Alzheimer disease
| journal = Alzheimer Disease and Associated Disorders
| volume = 10
| issue = 2
| pages = 93–102
| last2 = Antuono
| first2 = P. G.
| last3 = Delagandara
| first3 = J. E.
| last4 = McDonald
| first4 = M. A.
| last5 = Cutler
| first5 = N. R.
| last6 = Cohen
| first6 = S. R.
| last7 = Green
| first7 = R. C.
| last8 = Zemlan
| first8 = F. P.
| last9 = Crismon
| first9 = M. L.
| last10 = Alter
| first10 = M
| last11 = Shipley
| first11 = J. E.
| last12 = Reichman
| first12 = W. E.
 | doi=10.1097/00002093-199601020-00007
}}</ref>
}}

== See also ==
* [[Linopirdine]]
* [[Sibopirdine]]

== References ==
{{Reflist}}

[[Category:Nootropics]]